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Purpose or Objective: To evaluate the outcome of 
stereotactic body Vero® linac- or Cyberknife®-based 
radiotherapy (SBRT) for oligometastatic lymph node recurrent 
prostate cancer. 
 
Material and Methods: Between 05/2012 and 09/2015 117 
patients were treated (180 lymph nodes). Median age, initial 
PSA (iPSA), pre-SRT PSA and Gleason score (GS) were 70.3 
years, 10.3 ng/mL, 4.4 ng/mL and 7, respectively. Any 
previous treatment was allowed. In all but 4 patients, 
[11C]choline-positron emission tomography/computer 
tomography was performed. SBRT consisted in re-irradiation 
and first radiotherapy for 29 (16%) and 151 (84%) lesions, 
respectively. Median dose was 24 Gy/3 fractions. Cyberknife-
SBRT or Vero linac-SBRT was applied in 20 (11%) and 160 
(89%) lymph nodes, respectively. In 56 (48%) patients 
androgen deprivation was added to SBRT (median duration 
13.9 months), some patients were heavily pre-treated and 
castration-resistant. Biochemical failure was defined as post-
SBRT PSA increase over pre-SBRT value. Toxicity was 
evaluated using Radiation Therapy Oncology Group/European 
Organization for Research and Treatment of Cancer 
(RTOG/EORTC) criteria. 
 
Results: All patients completed planned SBRT. The median 
follow-up was 19.7 months. Acute toxicity included urinary (7 
G1 events) and rectal complications (2 G1 events). Late 
toxicity included only urinary complications (2, 2, and 2 G1, 
G2, and G4 events, respectively). Both G4 events were 
temporary and were observed in pts receiving re-RT, with no 
dose to bladder from SBRT. Complete or partial biochemical 
response was observed in 68(68%) out of 100 evaluable 
patients. PSA stabilization was seen for 7(7%) patients and in 
24(24%) cases PSA progression was reported. Clinical 
progression during follow up was observed in 65(65%) patients 
after a median time of 9 months (range: 1 – 33.1 months) 
from SBRT. In-field progression was observed in 13(13%) 
cases. 31(31%) patients had distant metastases and 34(34%) 
showed regional lymph node progression. All events of 
clinical failure were preceded by biochemical progression. At 
the time of the analysis (October 2015), 17(14.5%) patients 
are alive with no evidence of disease, 79(67.5%) are alive 
with clinically evident disease, 4(3.5%) died of disease and 
17(14.5%) are not evaluable (due to short follow-up). 
 
Conclusion: Our series including 117 unselected pts showed 
that Vero Linac- or Cyberknife-based SBRT is feasible for 
oligometastatic lymph node recurrent prostate cancer 
offering excellent in-field tumor control and low toxicity 
profile. Further investigation is warranted in order to identify 
the patients that benefit most from this treatment modality. 
The optimal combination with androgen deprivation or other 
systemic treatments should also be defined. 
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Purpose or Objective: The aim of our retrospective study 
was to analyze the role of [(11)C]choline-Positron Emission 
Tomography/Computed Tomography (cho-PET/CT) in the 
management of patients (pts) with biochemical failure after 
curative surgery in patients with prostate cancer. 
 
Material and Methods: We reviewed all patients referred to 
our department with biochemical failure and without 
evidence of recurrence on standard imaging (pelvic MRI + 
total body CT-scan) after curative surgery for prostate 
cancer. All patients underwent cho-PET/CT scans between 
2010 and 2014.  
 
Results: Thirty-four patients fulfilled the inclusion criteria 
and were included in this study. Previous surgical procedure 
was: radical prostatectomy (19 pts), radical prostatectomy 
with pelvic lymph node dissection (8 pts) and radical 
prostatectomy with lymph node sampling (9 pts). Thirty-six 
scan cho-PET/CT studies were performed on 34 patients. 
Median PSA level before cho-PET/CT was 1.7 ng/mL (range 
0.2 to 7.6). Cho-PET/CT showed 21 uptakes in prostate bed, 
4 in prostate bed and pelvic lymph nodes, 1 in prostate bed 
and paraaortic lymph nodes, 5 in pelvic lymph nodes, 1 in 
retroperitoneal lymph nodes (4 exams were negative). Eleven 
pts underwent salvage radiotherapy, 21 pts salvage 
radiotherapy and androgen deprivation therapy and 1 patient 
androgen deprivation therapy only. With a median follow-up 
of 15 months, 27 showed complete biochemical response to 
salvage therapy (PSA <0.04 ng\ml), and are still free from 
biochemical recurrence. Two pts showed biochemical failure, 
3 developed lymph node recurrence and 2 patients developed 
bone metastases.  
 
Conclusion: Cho-PET/CT was able to detect macroscopic 
disease in prostate cancer pts with biochemical failure after 
surgery allowing individualized salvage treatment. 
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Purpose or Objective: To retrospectively evaluate external 
beam re-irradiation (re-EBRT) delivered to either the 
prostate or prostatic bed for local recurrence after radical or 
adjuvant/salvage radiotherapy. 
 
Material and Methods: Between February 2008 and March 
2015, 59 patients received re-EBRT. Median age was 63.8 
years (range 47.1-81.7) and median PSA at the time of 
relapse was 20.2 ng/ml (range 4.4-110). All patients had 
clinical and/or radiological local relapse in the prostate or 
prostatic bed and no distant metastasis at the time of re-
EBRT. A concomitant hormonal treatment was administered 
to 18 patients. Re-EBRT was delivered with image-guided 
stereotactic technology including Rapid Arc®, VERO® and 
Cyberknife® to a total dose of 15-32 Gy in 3-6 fractions. 
Toxicity was evaluated using RTOG/EORTC Criteria. 
Biochemical control was assessed according to Phoenix 
definition. 
 
Results: Only one patient experienced an acute GI event 
>G3, while two patients had late ≥G3 urinary toxicity.  
At a mean and median follow-up of 24.1 and 19.8 months 
respectively (range 2-65.5), 27 patients (45%) show no 
evidence of disease, 26 (44%) are alive with biochemical or 
clinical disease and 2 have been lost at clinical follow-up. 4 
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patients (7%) died: 2 of disease progression and 2 of other 
causes. Mean and median time-to-progression are 12.1 and 
9.8 months respectively (range 2-53). 
 
Conclusion: Re-EBRT using stereotactic approach is a feasible 
option for local prostate cancer recurrence, achieving tumour 
control in 45% of the patients and an acceptable progression-
free interval. Toxicity of re-EBRT appeared to be very low. 
Future studies are needed to identify those patients who 
would benefit the most from this treatment. 
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Purpose or Objective: to evaluate the outcomes in 
intermediate risk prostate cancer treated with 
hypofractionated radiotherapy (HyRT) 
 
Material and Methods: Between March 2007 and March 2015, 
145 patients affected by intermediate risk (T2b–T2c prostate 
cancer or Gleason Score equal to 7 or pre-treatment PSA 
value ranging from 10 to 20 ng/mL) prostate cancer were 
treated with HyRT. The median age at diagnosis was 74 years 
(range 53-88). A pre-treatment CT scan with 2.5 mm slices 
was obtained. MRI was used to better delineate the Clinical 
Target Volume (CTV) when available. The CTV1 included the 
prostate plus seminal vesicles (SSVV) and the CTV2 the 
prostate alone. Planning Target Volumes (PTV1 and PTV2, 
respectively) were generated with 8 mm margin in all 
directions except posteriorly where a 6 mm expansion was 
adopted in the first 36 patients. A 5 mm expansion in all 
direction was used in the other patients as daily kv Cone 
Beam CT was used to verify the patient position because of 
an implementation of the linear accelerator. A 3D-CRT and a 
15 MV photons linear accelerator was used to deliver the 
treatment. The PTV1 received 43.8 Gy in 12 fractions and the 
PTV2 received 54.75 Gy in 15 fractions, three times a week in 
order to avoid an excess of acute toxicity. Neoadjuvant, 
concomitant and adjuvant ADT was administered for a total 
of 9 months and was started 3 months before RT. 
 
Results: After a median follow-up of 52.4 months (range 7 to 
95 months), 11 patients (7.6%) died, of whom 9 for 
intercurrent disease and 2 (1.3%) for PCa. The 5-year OS was 
90.1% (95%CI 84.2-97.6%) and the 5-year CSS was 98.6% 
(95%CI 95.4-100%). Fourteen patients (9.7%) developed 
biochemical recurrence after a median follow up of 30.5 
months (95% CI 28.5 to 32.5 months). Of these patients, 
thirteen (9.0%) had also a clinical detectable disease while 
the remaining patient presented only biochemical 
recurrence. The 5y-bRFS was 88.8% (95%CI 82.8-95.4%). 
Among the 13 patients with clinical recurrence, 7 (53.8%) had 
local recurrence, 2 (15.4%) developed distant metastases, 
and 4 (30.8%) had both local recurrence and distant 
metastases. Acute genito-urinary (GU) toxicity of grade 1 
occurred in 74 patients (51.0%), grade 2 in 15 patients 
(10.3%) and grade 3 in 2 patients (1.3%). Acute gastro-
intestinal (GI) toxicity of grade 1 were observed in 27 
patients (18.6%), grade 2 in 12 patients (8.2%). None 
developed acute GI toxicity of grade 3 or 4. Late GU toxicity 
occurred as follows: grade 1 in 51 patients (35.2%), grade 2 in 
12 patients (8.2%), grade 3 in 2 patients (1.3%). Late GI 
toxicity of grade 1 was observed in 18 patients (12.4%), grade 
2 in 6 patients (4.1%) and grade 3 in 1 patient (0.7%). 
 
Conclusion: The hypofractionated schedule used is well 
tolerated with a low rate of acute and late grade ≥ 2 
gastrointestinal and genitourinary toxicities. 
Hypofractionation is useful to obtain high rate of tumor 
control but a longer follow-up is needed for definitive 
conclusion. 
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Purpose or Objective: In the context of the multi-
institutional research project “Carbon ions boost followed by 
pelvic photon intensity modulated radiotherapy for high risk 
prostate cancer”, Contouring Guidelines (CG) for target 
volumes and Organs At Risk (OARs) were commonly defined 
based on National/International standards and local 
experiences. Intra- and inter-institutional variability was 
evaluated within a contouring dummy-run and a graphical 
tool was developed to assist the Radiation Oncologists (ROs) 
in the standardization of the contouring. 
 
Material and Methods: CT and MR images of 5 prostate 
patients were randomly chosen. Seven ROs belonging to the 
three Institutes involved in the project were assigned to 
independently contour targets (prostate (GTV-P), seminal 
vesicles (CTV-VS) and pelvic lymph nodes (CTV-N) and OARs 
(rectum (R), bladder (B), femoral heads (FH), small bowel 
(SB) , penile bulb (PB) and anal canal (AC). The registration 
between CT and MR images was only used to contour GTV-P 
and PB. The contours were compared by means of the DICE 
Index (defined as 2*(A∩B)/(A+B), where A e B are the 
volumes in comparison), as provided by the commercial 
software VODCA (MSS, v.5.4.0). For each structure, the 
Global DICE Index (GDI) was calculated as the average value 
for all the ROs and the patients and then compared with the 
DICE Index of the individual ROs: an individual DICE Index 
lower than the corresponding GDI (or lower than a threshold 
value of 0.9 for GDI > 0.9) was recorded as “disagreement” 
and reported in a graphical tool (Figure 1) that qualitatively 
shows intra- and inter-institutional variability. 
 
Results: The resulting GDI are reported in Table 1. A visual 
analysis of the contours on the CT images showed that the 
poor quality GDI for CTV-VS and AC were due both to a not 
strict application of the CG by the ROs of the different 
Institutes and to the small volume of those structures. The 
other results were instead attributable to random variation in 
the contouring. The graphical tool clearly showed that inter-
institutional variability was predominant compared to intra-
institutional variability both for targets and OARs. 
Nevertheless, some disagreement was found even between 
ROs of the same Institute. 
 
